速递｜华东医药发布HDM1005注射液2型糖尿病Ⅱ期临床试验结果，展现显著降糖减重效果

Core Viewpoint - The article highlights the positive results of the HDM1005 injection, a novel GLP-1/GIP dual-target long-acting agonist, in the treatment of type 2 diabetes, showcasing its efficacy in glycemic control, weight loss, and cardiovascular improvements [4][5][7]. Phase II Clinical Trial Results: Significant Glycemic Control and Weight Loss - The Phase II clinical trial involved 220 participants and demonstrated that after 20 weeks of treatment, HDM1005 achieved a maximum reduction in HbA1c of 2.57% across different dosage groups (0.5mg, 1.0mg, 2.0mg, 3.0mg), with HbA1c target rates of 86.5%, 83.3%, and 86.1% for the 1.0mg, 2.0mg, and 3.0mg groups respectively, compared to 25.7% in the placebo group [5] - In terms of weight loss, the percentage of participants who lost weight compared to baseline after 20 weeks was 28.2%, 48.6%, 50.0%, and 61.1% for the respective dosage groups, while the placebo group only saw a 2.9% reduction [5] Safety and Tolerability: Positive Clinical Profile - The safety and tolerability of HDM1005 were found to be good, with most adverse events being mild or moderate, and no serious adverse events related to treatment reported. Common adverse events included metabolic and nutritional disorders as well as gastrointestinal issues, with incidence rates similar to those in the placebo and dulaglutide groups [6] - The study noted only two cases of grade 1 hypoglycemia in the HDM1005 group, with no occurrences of grade 2 or higher hypoglycemia, indicating a safety profile comparable to other GLP-1 receptor agonists [6] Future Outlook: Comprehensive Clinical Benefits for Patients - HDM1005, as a dual-target long-acting agonist, shows significant effects in glycemic control, weight loss, and metabolic function improvement for type 2 diabetes. Two Phase III clinical studies in China have already commenced, with the first participant enrolled [7] - The preclinical studies indicate that HDM1005 can effectively improve blood sugar levels and reduce weight, offering multiple benefits including glycemic control, weight loss, and cardiovascular adaptability [7] - HDM1005 is not only advancing clinical trials in China but has also received FDA approval in the U.S. for clinical studies across multiple indications, including metabolic-associated fatty liver disease (MAFLD) and obstructive sleep apnea (OSA) with obesity [7] - As an innovative drug with global intellectual property rights, HDM1005 provides a new treatment option for type 2 diabetes patients and opens new avenues for treating metabolic-related diseases like diabetes and obesity, with its commercialization process expected to accelerate and have a profound impact on global diabetes treatment [7]